NCT06860529

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 357 (estimated)
• Sponsor: Henan Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The neoadjuvant treatment options commonly used for HR+/HER2- breast cancer are mainly anthracycline sequential or combined with paclitaxel chemotherapy regimens. Several clinical studies have confirmed that albumin paclitaxel is more effective than solvent-based paclitaxel, and therefore, albumin paclitaxel in combination with epirubicin has also become a commonly used chemotherapy regimen in clinical practice. The aim of this study was to explore the efficacy and safety of the Serplulimab combined with nab-paclitaxel and epirubicin in the neoadjuvant treatment of HR+/HER2- breast cancer

Conditions

• HR+/HER2- Breast Cancer

Interventions

Type	Name	Description
DRUG	Serplulimab	Serplulimab is administered intravenously
DRUG	Epirubicin	Epirubicin ivgtt
DRUG	Albumin Paclitaxel	Albumin Paclitaxel ivgtt

Timeline

• Start date: 2025-04-15
• Primary completion: 2028-03-31
• Completion: 2030-03-31
• First posted: 2025-03-06
• Last updated: 2025-06-23

Locations

1 site across 1 country: China